Adamis Pharmaceuticals (NSDQ:ADMP) said this week that it inked an exclusive deal with Novartis‘ (NYSE:NVS) Sandoz unit to distribute and commercialize its Symjepi emergency allergy treatment.
The agreement puts Novartis in the position to compete directly with Mylan‘s (NSDQ:MYL) EpiPen auto-injector. The pharma giant has been under pressure in recent months thanks to manufacturing delays that have caused an Epipen shortage in the U.S.
Get the full story at our sister site, Drug Delivery Business News.
The post Novartis steps in to compete with Mylan’s Epipen appeared first on MassDevice.
from MassDevice https://ift.tt/2IIMsDB
Cap comentari:
Publica un comentari a l'entrada